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INTRODUCTION
etastatic melanoma has shown only limited responsive-
ness to chemotherapy or immunotherapy. The median of
overall survival (OS) is 6 to 9 months and systemic therapy
induces complete response in a minor number of cases.
The most commonly used single-agent chemotherapy comes
from the nitrosourea group of agents and provides response rates
of less than 20%. Dacarbasine (DTIC), as the most active of these
compounds, remains the chemotherapy standard for metastatic
disease (1). Several cytotoxic agents have been combined with no
dramatic benefit (1). The incorporation of tamoxifen in chemother-
apy regimens has proven effective in some trials (2). However,
combinations of therapy, for example DTIC with other cytotoxic
agents, tamoxifen or cytokines, have largely proven to add toxici-
ty with no significant survival benefit (3). Interferon alpha (IFN
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BACKGROUND: Metastatic melanoma has shown only limited responsiveness to
chemotherapy or immunotherapy. The most commonly used single-agent chemother-
apy comes from the nitrosourea group of agents and provides response rates of less
than 20%. Several cytotoxic agents have been combined with no dramatic benefit. The
incorporation of tamoxifen or interferon in chemotherapy regimens has proven effec-
tive in some trials. 
METHODS: From July 1998 to March 2002, 45 patients with metastatic melanoma
were enrolled for the study. None of the patients had previously received chemothera-
py. The aim of the study was to compare the activity of three combined regimens: CVD
(cisplatin, vinblastine, dacarbazine) chemotherapeutic combination, CVD with interfer-
on (IFN) alpha-2 - biochemotherapy, and CVD with tamoxifen. The study was conduct-
ed as a single center, controlled, prospective, randomized phase II study directed
toward the disease.
RESULTS: The best response rate (RR) was observed in the CVD+IFN (6/15) group
related to the CVD (4/15) and CVD+TAM (3/15) groups, without significant difference
though. In 29 patients with 1 to 2 metastatic lesions, RR was 44.82% (CR-1, PR-12,
SD-13, PD-3), while in 16 patients with 3 or more metastatic lesions RR was 0.0 %
(CR-0, PR-0, SD-9, PD-7). The difference was statistically significant (p<0.005). The
best responding metastatic sites  were the lymph nodes (in 10 patients), but patients
with lung, skin and liver lesions also responded. All patients experienced mild adverse
effects. No treatment-related deaths occurred. The median survival was 12, 12, and 11
months in CVD+IFN, CVD and CVD+TAM group, respectively. Time to progression
was about 8 months in all treated groups.
CONCLUSION: Combined chemotherapy, biochemotherapy or chemohormonal thera-
py all showed some activity in metastatic melanoma. However, it is not yet possible to
define standard therapy for this disease. Due to a limited number of patients evaluated
so far in this investigation the results should be clearer and more conclusive with larg-
er cumulative number of cases enrolled.
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25alpha) as a single agent has been extensively studied in advanced
melanoma. When used as monotherapy, IFN alpha produced
overall response rates comparable with those achieved with sin-
gle-agent DTIC. The improvement when IFN alpha and
chemotherapy were used in combination was negligible or very
moderate in randomized phase III trials (4). The rationale for com-
bining cytostatics with IFN in melanoma lies in the assumed dif-
ferent antitumor mechanism. The wide spectrum of IFN-induced
immunomodulatory and antiproliferative effects together with the
antitumor activity of cytostatic agents may be additive or syner-
gistic (5). 
Aim of the study was to compare the activity of three combined
regimens (one of them containing the CVD chemotherapeutic
combination; one CVD with IFN alpha-2 - biochemotherapeutical;
and one CVD with tamoxifen).
PATIENTS AND METHODS
Patients. From July 1998 to March 2002, 45 patients (15 patients
per each group) with metastatic melanoma were enrolled for the
present study (Table 1). The treatment required 10 days hospital
admittance. None of the patients had previously received
chemotherapy.
Study type. Prospective, controlled randomized phase II disease-
directed study. The study was conducted in accordance with the
Helsinki Declaration standards of ethics (1964) amended in 1975,
1983, and 2000 by the World Medical Association.
Inclusion criteria. Histologically confirmed malignant melanoma;
metastatic disease with metastatic lesions inappropriate for radi-
cal surgery; measurable or assessable lesions; performance sta-
tus 0-2; expected survival over 2 months; and oral consent of the
patient.
Exclusion criteria. Patients who do not fulfill the inclusion criteria;
choroidal primary disease site; presence of unresectable CNS
metastases; voluminous liver metastases associated with hyper-
bilirubinemia or liver insufficiency; and other contraindications for
any of the planned drugs.
Treatment schedule. The patients were randomized in three
groups. The treatment regimen A consisted of dacarbazine 800
mg/m2 IV day 1, vinblastine 1.6 mg/m2 IV days 1-5, and cisplatin
20 mg/m2 IV days 1-4 (CVD). The cycle was repeated on day 22.
The treatment regimen B consisted of CVD chemotherapy plus
IFN alpha-2a (Roferon A, Roche) 1.5x106 IU/m2 days 1-10. The
treatment regimen C consisted of CVD chemotherapy plus tamox-
ifen 20 mg/m2, all the time. The total number of cycles/day was
6 at the most. Those with progressive disease were excluded
from the program after two cycles, while all the rest received six
cycles, including those with stable disease, partial and complete
remission.
Evaluation of response and toxicity. Pretreatment evaluation
included physical examination, complete blood count and organ
function tests. Staging was based on clinical and radiological
examinations. Physical status and adverse effects were recorded
and laboratory tests were taken every 4 weeks. Overall response
was evaluated every 6 weeks. The responses and adverse effects
were evaluated according to the World Health Organization criteria.
Statistical methods. The results obtained were evaluated accord-
ing to the methodology of descriptive and analytic statistics. For
hypothesis checking adequate parametric and non-parametric
statistic tests were used (Pearson c2 test). Survival analysis was
done according to Kaplan-Meier, with log-rank test of comparison
of two or more factors (6). The 95% confidence limits for
response rate were calculated using the normal approximation.
RESULTS 
Patients’ characteristics (Table 1) indicated that there was no sig-
nificant difference among the groups for the factor of patient age,
performance status (PS), and the number of anatomic sites
involved by metastatic process.
Therapeutic response is shown in Table 2. One complete remis-
sion (CR) was achieved in B group (CVD+IFN) in a female patient
with bilateral multiple metastatic lesions in the lungs; the remis-
sion lasted 14 months, with consequent lung relapse (up to the
evaluation time, total survival was 19 months).
Response rate was the highest best in CVD+IFN group (6/15)
compared to CVD (4/15) and CVD+TAM (3/15) groups, but the
difference was not significant (Figure 1).
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Table 1. Patients￿ characteristics
Table 2. Response rateResponse to treatment related to the number of involved anatom-
ic sites is shown in Figure 2. Out of 29 patients with 1-2 metasta-
tic sites, RR was 44.82% (CR-1, PR-12, SD-13, PD-3) while in all
groups with three or more involved sites 16 patients, RR was
0.0% (CR-0, PR-0, SD-9, PD-7). The difference was of high sta-
tistical significance (p<0.005). 
The best responding metastatic sites  were the lymph nodes (in
10 patients), but the patients with lung, skin and liver metastatic
deposits also responded (Table 3).
The reported toxicities associated with the treatment are shown in
Tables 4, 5, and 6. All patients experienced mild adverse effects.
Toxicity grade 3 and 4 were common in all the groups. The occur-
rence of nausea is understandable in view of the emetic agents
used, above all of cisplatin. Serotonin receptor (5-HT3) antago-
nists and metoclopramide were routinely given to prevent nausea
and vomiting during chemotherapy. Fever and arthralgias were
characteristic for the IFN group. One patient from the tamoxifen
Combined systemic treatment of melanoma
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Figure 1. Response to therapy
Table 3. Characteristics of responding patients
Table 4. Treatment toxicity in group A - CVD
Figure 2.  Response to therapy depending on the number of metastatic sites
Table 5. Therapy toxicity in group B - CVD+IFN
Table 6. Therapy toxicity in group C - CVD+TAM
Figure 3. Overall survival. Heavy line represents CVD + IFN group; Fine line repre-
sents CVD group; Interrupted line represents CVD + TAM group (p=0.824, N.S.)group had deep vein thrombosis. No treatment-related deaths
occurred. Total patients survival is shown in Figure 3, and time to
progression (TTP) is shown in Figure 4. 
DISCUSSION AND CONCLUSION
Response rates in this study ranged between 20% and 40%
(CVD+IFN 6/15, CVD 4/15, CVD+TAM 3/15), i.e., 28.8% if all
the cases were analyzed together. This is comparable with many
studies performed during the 1990s. One of the most marked
deviations from these results was a Finish phase II study with the
response rate of 62% achieved with combined chemotherapy and
human leukocyte interferon alfa (7). Liver metastases accounted
for more then 50% in our study, as opposed to 21% in
Pyrhoenen’s study. Liver metastases are shown to be more resis-
tant to any kind of chemotherapy or immunotherapy, especially
liver metastases of ocular melanoma.
In two prospective randomized trials, a therapeutic advantage in
the response rate or in the duration of response has been report-
ed with the combination of IFN and dacarbazine compared to
dacarbazine alone (8). The results of our study correspond to a
later phase III study by Falkson et al. (4). However, it should be
emphasized that response rates were higher with combined IFN-
alpha and chemotherapy compared to chemotherapy alone and,
two times higher than with combined chemotherapy and tamox-
ifen. Extra toxicity was not observed, at least with these IFN alpha-
2a doses.
The MD Anderson study, comparing biochemotherapy to combi-
nation therapy, demonstrated doubling of objective response
rates (48% versus 25%; p=0.001) and time to progression of
disease (4.9 months versus 2.4 months: p=0.008) but no advan-
tage for overall median survival (18.7 months versus 15.4
months: p=0.99) (9). These findings generated renewed enthu-
siasm for biochemotherapy. The results of our study agree with
these results. Time to progression in our study was somewhat
higher (7.17 to 9.31 months) with overall median survival some-
what lower (10.47 to 13.51) though without significant difference
among the groups for TTP as well as for OS. The United States
intergroup study of IL-2/IFN + CVD versus CVD was closed after
randomizing 397 patients (10). Primary end points included
response, survival, and time to progression. The median OS was
8.1 months for biochemotherapy compared with 8.7 months for
chemotherapy alone (p=0.439); time to progression was about 4
months for biochemotherapy and approximately 2 months for
chemotherapy (p=0.082). Significantly more toxicity was noted
the biochemotherapy arm.
In view of a small number of examinees, we may point out as a
conclusion that standard systemic therapy still cannot be defined
for metastatic melanoma. 
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Figure 4. Time to progression. Heavy line represents CVD + IFN group; Fine line rep-
resents CVD group; Interrupted line represents CVD + TAM group (p=0.758 N.S.)
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